JP2024506709A5 - - Google Patents
Info
- Publication number
- JP2024506709A5 JP2024506709A5 JP2023549575A JP2023549575A JP2024506709A5 JP 2024506709 A5 JP2024506709 A5 JP 2024506709A5 JP 2023549575 A JP2023549575 A JP 2023549575A JP 2023549575 A JP2023549575 A JP 2023549575A JP 2024506709 A5 JP2024506709 A5 JP 2024506709A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- aso
- oligonucleotide
- bases
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150188P | 2021-02-17 | 2021-02-17 | |
| US63/150,188 | 2021-02-17 | ||
| PCT/US2022/016842 WO2022178160A1 (en) | 2021-02-17 | 2022-02-17 | Ube3a antisense therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506709A JP2024506709A (ja) | 2024-02-14 |
| JP2024506709A5 true JP2024506709A5 (enExample) | 2025-02-25 |
Family
ID=82802019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549575A Pending JP2024506709A (ja) | 2021-02-17 | 2022-02-17 | Ｕｂｅ３ａアンチセンス治療剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220259601A1 (enExample) |
| EP (1) | EP4294925A1 (enExample) |
| JP (1) | JP2024506709A (enExample) |
| CA (1) | CA3211396A1 (enExample) |
| WO (1) | WO2022178160A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025128816A1 (en) * | 2023-12-13 | 2025-06-19 | Kicho Inc. | Methods of modulating expression of ube3a gene |
| WO2025128853A2 (en) | 2023-12-13 | 2025-06-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
| WO2025132962A2 (en) * | 2023-12-21 | 2025-06-26 | F. Hoffmann-La Roche Ag | Antisense oligonucleotide |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
| US6617442B1 (en) * | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| ES2526295T5 (es) * | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| PE20090064A1 (es) * | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| US20150322428A1 (en) * | 2012-06-18 | 2015-11-12 | Isis Pharmaceuticals, Inc. | Compounds and methods for improved cellular uptake of antisense compounds |
| US11077132B2 (en) * | 2015-02-04 | 2021-08-03 | F. Hoffmann-La Roche Ag | Tau antisense oligomers and uses thereof |
| PT3947684T (pt) * | 2019-03-29 | 2025-05-19 | Ionis Pharmaceuticals Inc | Compostos e métodos para modular ube3a‑ats |
-
2022
- 2022-02-17 US US17/674,692 patent/US20220259601A1/en active Pending
- 2022-02-17 EP EP22756950.6A patent/EP4294925A1/en active Pending
- 2022-02-17 WO PCT/US2022/016842 patent/WO2022178160A1/en not_active Ceased
- 2022-02-17 CA CA3211396A patent/CA3211396A1/en active Pending
- 2022-02-17 JP JP2023549575A patent/JP2024506709A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506709A5 (enExample) | ||
| Mercatante et al. | Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases | |
| US20140066491A1 (en) | Chemical modification motifs for mirna inhibitors and mimetics | |
| JP2012147790A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| Sharma et al. | The therapeutic potential of antisense oligonucleotides | |
| KR20230043912A (ko) | Lpa 발현을 저해하기 위한 조성물 및 방법 | |
| US9163235B2 (en) | Inhibitors of the miR-15 family of micro-RNAs | |
| NZ572199A (en) | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene | |
| JP2009508527A (ja) | グルココルチコイド受容体発現の調節 | |
| MX2011008190A (es) | Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos. | |
| AU2019234917B2 (en) | Inhibitors of micro-RNA 22 | |
| JP2009535039A5 (enExample) | ||
| JP7634542B2 (ja) | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 | |
| JP2026500220A (ja) | 高度ｒｎａ標的化（ａｒｎａｔａｒ） | |
| JP2025166835A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 | |
| JP2023542889A5 (enExample) | ||
| CA3211396A1 (en) | Ube3a antisense therapeutics | |
| JP2024073525A5 (enExample) | ||
| JP2023538630A (ja) | Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用 | |
| JP2024515240A5 (enExample) | ||
| JP2021513851A5 (enExample) | ||
| CN114829601A (zh) | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| CN115551519A (zh) | 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法 | |
| JP2024518788A5 (enExample) | ||
| JP2022524218A (ja) | Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 |